101 results about "Osteosarcoma" patented technology

The invention relates to the technical field of image recognition, in particular to an osteosarcoma image intelligent recognition and classification method and system based on an image recognition model. The method comprises the following steps: collecting a tumor image and carrying out multi-sequence disturbance equilibrium enhancement to generate an enhanced block tumor image, then obtaining a color standardized image through color space transformation remapping, then extracting a tumor region image and carrying out contrast inversion processing, reconstructing a tumor feature image, and finally, carrying out multi-sequence disturbance equilibrium enhancement on the tumor feature image. Based on a preset image recognition model, tumor edge features are recognized, the edge rule degree is determined, preliminary classification is carried out, a benign tumor image is obtained, surrounding metabolite signal features of the benign tumor image are analyzed, a benign reference group is formed through combination, metabolism state comparison is carried out on tumor feature images, and metabolism difference data are generated. And performing category correction according to the metabolic state mapping data so as to identify the osteosarcoma category. According to the invention, intelligent analysis of tumor features is realized, the image processing flow is optimized, and the processing efficiency is improved.

The invention discloses a pelvic soft osteosarcoma MRI (Magnetic Resonance Imaging) segmentation method based on edge-guided multi-scale fusion. The method comprises the following steps: firstly, acquiring an MRI image of a patient with soft osteosarcoma of pelvis, and preprocessing the image; and then, constructing a pelvic soft osteosarcoma MRI segmentation network model, namely an EMU-Net segmentation network, based on edge-guided multi-scale fusion. And training the network by using the preprocessed training data, inputting a pelvic soft osteosarcoma MRI image to be segmented into the trained network, outputting a corresponding segmentation probability graph, and obtaining a final tumor segmentation mask by setting a threshold value. The method not only effectively overcomes the clinical segmentation bottleneck, but also realizes full-automatic and high-efficiency precise segmentation by means of an end-to-end deep learning architecture, and has remarkable advantages in the aspects of precision and robustness.

The invention relates to the technical field of image recognition, in particular to a multi-scale osteosarcoma CT image lesion area detection method based on feature distillation. The method comprises the following steps: acquiring a multi-scale osteosarcoma CT image and an attachment area image, performing forged image difference reduction to generate a unified CT image, reconstructing a three-dimensional tumor body form, extracting a bone attachment structure, performing relocation registration to obtain tumor body relocation data, and then generating a simulation attachment area framework based on the data, the method comprises the following steps: performing static feature distillation on a three-dimensional tumor body form to obtain an edge contour, defining an initial attachment area frame, performing feature comparison through a historical contour image to extract form change, evaluating the erosion degree of the attachment frame, and finally screening candidate lesion areas and positioning osteosarcoma lesion areas according to change areas. According to the invention, more efficient multi-source heterogeneous image data integration, more accurate three-dimensional tumor simulation reconstruction and clearer lesion area detection are realized.

The invention relates to application of an SLC30A9 inhibitor in preparation of an anti-tumor medicine, and belongs to the technical field of biological medicines. The invention provides an application of an SLC30A9 inhibitor in preparation of an anti-tumor drug. The expression of SLC30A9 is down-regulated to activate a cGAS-STING-NF-kappa B pathway, so that apoptosis of osteosarcoma cells is promoted, killing of the osteosarcoma cells by MTX is enhanced, and sensitivity of the osteosarcoma cells to MTX chemotherapy is recovered. Through combined application of SLC30A9 knock-down, a cGAS-STNG-NF-kappa B pathway agonist and MTX for chemotherapy, the killing effect of MTX on osteosarcoma cells can be remarkably enhanced, tumor cell proliferation is inhibited, and the treatment effect is improved. The core effect of the SLC30A9 in an osteosarcoma chemotherapy drug resistance mechanism is defined, and a theoretical basis and a technical support are provided for subsequent development of targeted drugs aiming at a cGAS-STNG-NF-kappa B pathway.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The application discloses a kind of thieno [2, 3-c] pyrazole compounds in preparation antitumor drug purposes, belong to pharmaceutical chemistry technical field.The application provides a kind of small molecule skeleton thieno [2, 3-c] pyrazole compound I and II, compound I is 2-oxo benzo [d] [1, 3] oxathiole-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-carboxylate.Compound II is 1-(4-chlorophenyl)-N-[4-((4-ethylpiperazine-1-yl)methyl)phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl.Both have strong antitumor activity.Compound II has strong inhibition to a variety of human tumor cells, such as bone sarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, provides new candidate compounds for broad-spectrum antitumor drugs.

The invention relates to anti-GD2 antibody-drug conjugates, compositions comprising the same and uses thereof in the treatment of osteosarcoma.

The invention discloses an application of targeted improvement of a high-potassium microenvironment in osteosarcoma immunotherapy, vanadium disulfide nano-particles are synthesized by taking vanadyl acetylacetonate as a raw material and adopting a high-temperature oil phase method, the particles can be accelerated to decompose at 42 DEG C or above so as to release hydrogen sulfide and vanadate, the vanadate can be specifically combined with E2 conformation of Na < + >-K < + >-ATP enzyme, and thus the stability of the particles is improved. According to the present invention, the HSP protein is released, the conversion of the HSP protein to E1 conformation is blocked, the continuous inward flow of K < + > is inhibited, such that the potassium ion concentration in the T cell is reduced, the function inhibition on the T cell is relieved, and the released hydrogen sulfide can further enhance the thermal effect by inhibiting the HSP protein so as to form the ion regulation-immune activation dual mechanism to improve the T cell killing ability. According to the scheme, the high potassium ion level of the osteosarcoma microenvironment is regulated and controlled through vanadate, hydrogen sulfide can enhance immune response and improve the anti-tumor function of T cells by enhancing the heat effect and the synergistic effect of vanadate, and an efficient and low-toxicity new strategy is provided for osteosarcoma treatment.

The invention relates to a polyethylene glycol medicine as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, an intermediate compound as shown in a formula II-XX, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibition effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The invention relates to the technical field of biological medicines, and particularly discloses a nanocapsule SMCPM and application thereof in medicines for treating or preventing osteosarcoma and pulmonary metastasis. The SMCPM is composed of a photosensitizer Ce6 carried by mesoporous silicon oxide-manganese oxide particles, an NRF2 inhibitor ML385 and an OS targeting peptide PT-7. Experiments prove that the SMCPM is high in penetrating power and strong in cell killing effect; by down-regulating NRF2 expression and reversing nuclear translocation, a biochemical inhibitory microenvironment can be effectively repaired, the tolerance of cells to active oxygen and epithelial-mesenchymal transition activated and induced by a NOTCH1 signal axis are remarkably reduced, the oxidative stress level of the cells is enhanced, and PIT-induced immunogenic cell death is promoted; the released Mn < 2 + > and double-stranded DNA can regulate and control an immunosuppressive microenvironment by activating an STING pathway in cells, thereby inhibiting the growth of osteosarcoma and preventing lung metastasis.

The present application relates to a kind of polycyclic polyketone compounds and its preparation method, pharmaceutical composition and application, the chemical structure type of the polycyclic polyketone compound is different from existing anti-osteosarcoma chemotherapy drug, it is compound with brand-new structure, while inventor finds that the polycyclic polyketone compound has significant anti-osteosarcoma cell 143B and U2OS activity by experiment, the anti-osteosarcoma activity of part compound is better than positive control drug, the result further indicates that the polycyclic polyketone compound of the present application can significantly inhibit the growth of osteosarcoma, and it is expected to develop into a new type of anti-osteosarcoma drug, can be used for treating osteosarcoma and the disease caused by bone and joint pain and lung disease.Further, the synthesis route of the polycyclic polyketone compound used in the present application is efficient and simple, and has good raw material economy.

The invention discloses application of a thieno [2, 3-c] pyrazole compound in preparation of antitumor drugs, and belongs to the technical field of medical chemistry. The invention provides a small molecular skeleton thieno [2, 3-c] pyrazole compound I and a small molecular skeleton thieno [2, 3-c] pyrazole compound II, and the compound I is 2-oxobenzo [d] [1, 3] oxathiacyclopentane-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formate. And the compound II is 1-(4-chlorphenyl)-N-[4-((4-ethyl piperazine-1-yl) methyl) phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl. The two compounds have relatively strong anti-tumor activity. Wherein the compound II has a relatively strong inhibition effect on various human tumor cells such as osteosarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, and a new candidate compound is provided for broad-spectrum antitumor drugs.

An injectable hydrogel for inhibiting osteosarcoma growth and its component preparation method are disclosed. The hydrogel is composed of curcumin nanoparticles, nano-hydroxyapatite, and methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth combines the antitumor properties of curcumin nanoparticles, the osteogenic ability and good mechanical strength of nano-hydroxyapatite, and the porous structure and injectability of methacryloxychitosan. This injectable hydrogel for inhibiting osteosarcoma growth exhibits a significant killing effect on osteosarcoma cells and simultaneously promotes the proliferation of mouse embryonic pre-osteoblasts. Through its synergistic antitumor and osteogenic dual functions, this hydrogel shows promising application prospects in postoperative treatment of osteosarcoma.

The invention discloses a preparation method of an injectable bismuth-based metal repairing agent, which comprises the following steps of: putting weighed bismuth, indium, tin and zinc metals into a crucible, putting the crucible into a vacuum high-temperature smelting furnace, heating the mixed metals in a vacuum environment until the mixed metals are completely molten by adjusting the smelting temperature, stirring and shaking the formed molten alloy, and then cooling the molten alloy to obtain the injectable bismuth-based metal repairing agent. And ensuring that four elements of bismuth, indium, tin and zinc are uniformly distributed in the alloy, naturally cooling the fully and uniformly mixed molten alloy, and solidifying to obtain the solid injectable bismuth-based metal repairing agent. The repairing agent can be used for treating osteosarcoma, firstly, the repairing agent is injected into a medullary cavity, so that the repairing agent is solidified in situ to form an internal fixing structure, then a magnetocaloric effect is triggered through an alternating magnetic field to induce osteosarcoma immunogenic death, and integrated treatment of tumor removal and bone repair is achieved. According to the scheme, the biological safety and the osseointegration function are achieved, the magnetic-thermal conversion process is efficient, and the good treatment effect on osteosarcoma is achieved.

The invention relates to an aloe-emodin piperazine derivative as well as a preparation method and application thereof, and belongs to the technical field of medicine synthesis. The aloe-emodin piperazine derivative is obtained by taking aloe-emodin as a raw material, substituting 15-site alcoholic hydroxyl of the aloe-emodin with piperazine and then connecting the 15-site alcoholic hydroxyl with a natural compound with anti-tumor activity and a derivative of the natural compound by utilizing different connecting arms. In-vitro anti-tumor experiments of the aloe-emodin piperazine derivative show that the aloe-emodin piperazine derivative has good anti-tumor activity on human cervical cancer cells (HeLa), human liver cancer cells (HepG2), human lung cancer cells (A549) and human osteosarcoma cells (U2OS), is expected to be developed into drugs for treating cervical cancer, osteosarcoma, lung cancer or liver cancer and other cancers, and has wide clinical application prospects.

The present disclosure relates to pharmaceutical compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, optionally for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

The invention belongs to the technical field of biomedicine, particularly relates to application of exosome miRNAs (micro Ribonucleic Acid) as a molecular marker for early diagnosis of osteosarcoma, and relates to biomarkers which are exosomes miR-9-5p, miR-3960, miR-200b-3p, miR-204-5p, miR-95-3p, miR-885-5p, miR-574-5p and miR-125b-5p. The invention also provides a kit for diagnosing osteosarcoma by using the exosome miRNAs, and the exosome miRNAs are used for preparing the kit for early diagnosis of osteosarcoma. According to the biomarker provided by the invention, the effective rate of early diagnosis of osteosarcoma is remarkably improved, and powerful support is provided for early discovery of osteosarcoma.

The invention discloses application of sulfonamide pyrrole compounds in preparation of anti-cancer drugs, and belongs to the technical field of medical chemistry. The invention provides sulfonamide pyrrole small molecule compounds with broad-spectrum anti-tumor potential, namely a compound I and a compound II. In-vitro pharmacological experiment results show that the compound I and the compound II show remarkable proliferation inhibition activity on various human tumor cell lines such as breast cancer HCC1806, osteosarcoma MG63, colorectal cancer HCT-8, liver cancer LM3 and lung cancer A549, and the inhibition effect is concentration-dependent. The results show that the sulfamido pyrrole compound has a good application prospect in research and development of anti-tumor drugs, and can be used as a candidate molecule for developing novel broad-spectrum anti-tumor drugs.

The application discloses application of GCLC in enhancing cell uptake of BNCT drugs. Boron neutron capture therapy (BNCT) has become a promising method for treating osteosarcoma, and the treatment effect depends to a great extent on 10 Accumulation and distribution of B compounds in tumors. The application provides a gene marker capable of enhancing tumor cell uptake of BNCT drugs and application thereof, and proves that targeting GCLC can overcome the limitation of tumor heterogeneity on BNCT drug uptake by utilizing tumor-specific vulnerability.

This invention discloses a monoclonal antibody targeting HSP90 and its application. The monoclonal antibody targeting HSP90 can effectively inhibit the tumorigenicity and invasiveness of breast cancer cells, lung cancer cells, and osteosarcoma cells, and can significantly inhibit tumor growth in vivo. This invention provides a new targeted drug for diseases or symptoms related to high expression of HSP90, with broad prospects for clinical application.

The invention discloses a hypoxia activating peptide-photosensitizer-drug conjugate and a preparation method and application thereof in the technical field of medicine, the conjugate takes indocyanine with a high molar extinction coefficient as a photosensitive core, distorted conjugate units are introduced to two sides of indole, the characteristic of'limited movement in molecules' is given to the conjugate, and radiation and non-radiation energy dissipation are balanced. Meanwhile, an azo bond sensitive to hypoxia is reasonably introduced between a light treatment module and a chemotherapy module to serve as a responsive linker, and is further coupled with two-molecule integrin targeting peptide cRGD, so that the azo bond is self-assembled into nanospheres in an aqueous solution, and a triple targeting mechanism, namely multivalent integrin receptor targeting, aggregation and tumor microenvironment hypoxia selective activation, is realized. In an in-situ osteosarcoma mouse model, the conjugate realizes real-time near-infrared two-region imaging, shows potent tumor inhibition, effectively inhibits lung metastasis, and does not detect obvious systemic toxicity.

The invention provides a nitrogen-containing polycyclic aromatic compound as well as a preparation method and application thereof. The nitrogen-containing polycyclic aromatic compound has a structure as shown in a formula I and has excellent broad-spectrum anti-tumor activity. The compound especially shows a certain degree of inhibition rate on gastric cancer cells AGS, cervical cancer cells Hela, cervical cancer cells SiHa, lung cancer cells A549, liver cancer cells HuH-7, liver cancer cells Mahlavu, breast cancer cells MCF-7, triple negative breast cancer MDA-MA-231, colon cancer cells HCT116, esophageal squamous cell carcinoma TE-1, pancreatic ductal adenocarcinoma SUIT-2, multiple myeloma KMS-11, osteosarcoma U-2 OS, endometrial cancer HEC-151, colorectal cancer DLD-1 and the like. Therefore, the compound shown in the formula I can be used as a lead compound for research of novel broad-spectrum antitumor drugs.

The invention discloses an anti-tumor application of a thiazole compound, and belongs to the technical field of medical chemistry. The thiazole compound is 3-[(4-fluorophenyl) thio]-N-[4-(pyridine-2-yl) thiazole-2-yl] propanamide, and the English name of the thiazole compound is 3-((4-fluoropheyl) thio)-N-(4-(pyridin-2-yl) thiazol-2-yl) propanamide. The structural formula of the thiazole compound is shown in the description. The invention provides the thiazole compound with broad-spectrum anti-tumor activity, the compound has relatively strong inhibitory activity on clinical refractory breast cancer, osteosarcoma, colorectal cancer, liver cancer and lung cancer, and a new candidate compound is provided for broad-spectrum anti-tumor drugs.

The invention discloses a method for preventing lung relapse of cancer by using a cis-platinum lipid complex, and particularly discloses application of an inhalation type cis-platinum lipid complex (ILC) in preparation of a medicine for preventing or delaying osteosarcoma lung metastasis postoperative relapse or primary lung cancer postoperative relapse.

The application belongs to the field of antitumor drug chemistry, and discloses application of a selective PRMT4 inhibitor, deacetylganoderic acid F, in a drug for resisting drug-resistant osteosarcoma. The deacetylganoderic acid F has the following structure: it forms a unique hydrogen bond effect and binding mode with PRMT4, is a PRMT4 selective inhibitor, has the characteristics of strong enzyme inhibition selectivity, small toxic and side effects, and strong anti-drug-resistant osteosarcoma effect, and can be used as an anti-drug-resistant osteosarcoma drug. Mechanism research shows that the deacetylganoderic acid F can regulate the active oxygen level to play an anti-drug-resistant osteosarcoma role. The problems of poor selectivity and large toxic and side effects of existing PRMT4 inhibitors are solved, and a new drug selection is provided for the treatment of drug-resistant osteosarcoma.

The present invention addresses the problem of developing a novel drug for treating osteosarcoma. The present invention also addresses the problem of developing a therapeutic marker for studying the therapeutic effect of a drug in the treatment of osteosarcoma. The present invention shows that in order to solve the above-mentioned problem, a compound capable of inhibiting cell proliferation of osteosarcoma is found, and thus a novel pharmaceutical composition for treating osteosarcoma can be provided. It is also shown that osteosarcoma to be treated, which is a novel pharmaceutical composition, is an osteosarcoma in which the number of copies of an MCL1 gene in a cell has been increased or an osteosarcoma in which the production of an Mcl-1 protein has been increased, or an osteosarcoma in which the number of copies of a BCL2L1 gene has been increased or an osteosarcoma in which the production of a Bcl-xL protein has been increased. Therefore, by detecting these, it can be used as a therapeutic marker for studying the therapeutic effect of a novel pharmaceutical composition for the treatment of osteosarcoma.

The invention discloses a preparation method and application of a titanium-based nano material for enhancing osteosarcoma sonodynamic therapy. The preparation method comprises the following steps: 1, preparing a titanium dioxide nano material; 2, calcining after drying to obtain oxygen vacancy modified titanium dioxide; 3, preparing palladium modified titanium dioxide rich in oxygen vacancies; and 4, dispersing the palladium-modified titanium dioxide rich in oxygen vacancies into a folic acid-polyethylene glycol-sulfydryl solution, violently stirring, and then centrifuging and washing to obtain the titanium-based nano material. Titanium dioxide with sound-sensitive performance is used as a carrier, oxygen vacancies are introduced to modify the surface of the carrier, the sonodynamic performance of the material is remarkably enhanced, the palladium element is further loaded to improve the generation efficiency of active oxygen, folic acid is used for surface modification, so that the biocompatibility and tumor targeting ability of the material are improved, and the preparation method is simple and easy to implement. Functional integration of tumor targeted delivery and sonodynamic treatment is achieved, and the comprehensive treatment effect on osteosarcoma is remarkably enhanced.